Across TCGA pan-cancer cohorts, IGLV3-9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGLV3-9 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher IGLV3-9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV3-9 expression acts as an unfavorable survival marker.
SKCM, LIHC, and LUSC are the cancer types where IGLV3-9 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.